These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26347034)

  • 1. Alpha-synuclein propagation: New insights from animal models.
    Dehay B; Vila M; Bezard E; Brundin P; Kordower JH
    Mov Disord; 2016 Feb; 31(2):161-8. PubMed ID: 26347034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo models of alpha-synuclein transmission and propagation.
    Recasens A; Ulusoy A; Kahle PJ; Di Monte DA; Dehay B
    Cell Tissue Res; 2018 Jul; 373(1):183-193. PubMed ID: 29185072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion-like propagation of α-synuclein in neurodegenerative diseases.
    Tarutani A; Hasegawa M
    Prog Mol Biol Transl Sci; 2019; 168():323-348. PubMed ID: 31699325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
    Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
    Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.
    Valera E; Monzio Compagnoni G; Masliah E
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):95-106. PubMed ID: 26924723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
    Kahle PJ
    Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.
    Olsen AL; Feany MB
    Glia; 2019 Oct; 67(10):1933-1957. PubMed ID: 31267577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and models of alpha-synuclein-related neurodegeneration.
    Springer W; Kahle PJ
    Curr Neurol Neurosci Rep; 2006 Sep; 6(5):432-6. PubMed ID: 16928354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.
    Rey NL; George S; Brundin P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):51-76. PubMed ID: 26666838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of α-synuclein propagation and braak hypothesis.
    McCann H; Cartwright H; Halliday GM
    Mov Disord; 2016 Feb; 31(2):152-60. PubMed ID: 26340605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.
    McCormack AL; Di Monte DA
    Curr Protein Pept Sci; 2009 Oct; 10(5):476-82. PubMed ID: 19538156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein and transgenic mouse models.
    Fernagut PO; Chesselet MF
    Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Partners of α-Synuclein in Health and Disease.
    Lassen LB; Reimer L; Ferreira N; Betzer C; Jensen PH
    Brain Pathol; 2016 May; 26(3):389-97. PubMed ID: 26940507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Transcellular Propagation and Intracellular Trafficking of α-Synuclein.
    Tofaris GK; Goedert M; Spillantini MG
    Cold Spring Harb Perspect Med; 2017 Sep; 7(9):. PubMed ID: 27920026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.
    Vicente Miranda H; Szego ÉM; Oliveira LMA; Breda C; Darendelioglu E; de Oliveira RM; Ferreira DG; Gomes MA; Rott R; Oliveira M; Munari F; Enguita FJ; Simões T; Rodrigues EF; Heinrich M; Martins IC; Zamolo I; Riess O; Cordeiro C; Ponces-Freire A; Lashuel HA; Santos NC; Lopes LV; Xiang W; Jovin TM; Penque D; Engelender S; Zweckstetter M; Klucken J; Giorgini F; Quintas A; Outeiro TF
    Brain; 2017 May; 140(5):1399-1419. PubMed ID: 28398476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
    Chavarría C; Souza JM
    Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.